Pfizer reports stronger-than-expected results and updates its guidance for the year, raising its full-year revenue and profit outlook. Seeking Alpha and Quartz both describe higher forecast ranges for revenue for 2026, indicating the company is lifting the top end of what it previously expected.
Across outlets, the emphasis differs slightly in what gets highlighted. Seeking Alpha focuses on the longer-term framing, including projected revenue growth and adjusted earnings for 2026, tying the outlook to targets over later years. Quartz instead leads with the immediate outcome—beating earnings expectations—and the resulting changes to full-year sales and profit guidance, detailing the size of the increase and the updated revenue range. Another Quartz headline reiterates the forecast increase after the earnings beat, using a shorter description.
Overall, all sources agree Pfizer raises its 2026 revenue guidance to a range of about $62 billion to $64 billion after an earnings beat, with related profit guidance also moving higher.